Nandrolone: short ester

Nandrolone Phenylpropionate (NPP)

Nandrolone phenylpropionate (NPP) is the phenylpropionate ester of nandrolone, and the app's half-life is about 60 hours; none of the sources cited reports a half-life for NPP in people.1

Moderate evidence (the app's grade, not a conclusion of the sources)Get the app

Level after one dose

Nandrolone Phenylpropionate (NPP) after one dose: 50% at ~2.5 days, 25% at 5 days, 12.5% at 7.5 days.

Drawn from the half-life in the app's model, ~2.5 days. The model's figures

Nandrolone phenylpropionate (NPP) is the phenylpropionate ester of nandrolone (19-nortestosterone), with the molecular formula C27H34O3 and a molecular weight of 406.6 in PubChem.1 Its listed names include nandrolone phenpropionate and Durabolin, and a Cochrane review describes a 1973 trial of "nandrolone phenylpropionate (Durabolin)".1,2 Kicman, British Journal of Pharmacology, 2008, lists phenylpropionate among the nandrolone esters and writes that after injection "hydrolysis rapidly occurs by the action of blood esterases to yield the active compound".3

A search of PubMed on 16 November 2026 for nandrolone phenylpropionate, nandrolone phenpropionate or phenylpropionate nandrolone in the title or summary returned 79 records, among them the clinical reports below.4 A search of the US DailyMed label database on the same date returned 0 labels for the names nandrolone phenpropionate, nandrolone phenylpropionate and Durabolin, and 1 label for nandrolone, a nandrolone decanoate injection.5 A search of Health Canada's Drug Product Database for the ingredient name nandrolone returned 2 products, both nandrolone decanoate.6

The figures row above (half-life, bioavailability, typical dose and time to peak) is the app's own and is not taken from the sources cited. The sources cited below give no numeric half-life, bioavailability, time to peak or weekly regimen for NPP in people, and the pharmacokinetics and doses sections set the app's figures beside what they do report.

2

How it works

Sources in this part

  1. 3Kicman, 2008

Kicman writes that nandrolone "is readily converted by the enzyme 5α-reductase into 5α-dihydro-19-nortestosterone" in androgenic tissue, and that this metabolite "binds with weaker affinity to the androgen receptor compared with the parent steroid".3 Kicman adds that in skeletal muscle 5α-reductase activity is negligible, and "there is a greater myotrophic-to-androgenic ratio when compared with testosterone".3 The same review states that "complete dissociation has not been achieved with any anabolic steroid synthesized".3 Kicman cites in vitro studies showing 5α-reductase activity "very high in rat sexual tissue", writes of the "many failings" of the procedures for determining the myotrophic–androgenic index, and says it drew "The harshest criticism" from several authors.3 Kicman introduces the extension of this mechanism to human non-genital tissues with "If the model is correct".3

On the ester, Kicman writes that "The duration of action of the esters depends upon the rate of absorption from the site of administration" and that "In general, the longer the chain length, the more slowly the preparation is released into circulation".3 Kicman is a single-author review from the Drug Control Centre, King's College London, and states no conflict of interest; it describes nandrolone and its esters as a class and is not a study of NPP.3

3

Half-life and pharmacokinetics

Values from the Milligram app's model.

Half-life
~2.5 days
Bioavailability
95%
Typical dose
100–300 mg/week
Route
IM
Time to peak
~24 h

The app's figures are a half-life of 60 hours (about 2.5 days), a bioavailability of 95%, a time to peak of 24 hours and a duration of 72 hours, and the table sets what the sources report beside them.

Table 3.1Half-life and pharmacokinetics5 rows
MeasureApp figureSource figure
Half-life~2.5 days (60 h)No elimination half-life for NPP is given in the sources cited. Belkien and colleagues, 1985, reported half-lives of 8 days for nandrolone decanoate and 21 days for 19-nortestosterone-3-(p-hexoxyphenyl)-propionate in 6 men given 50 mg, which is a different ester from NPP.7
Bioavailability95%No percentage is given in the sources cited. Minto and colleagues, 1997, reported higher and earlier peaks of plasma nandrolone with the phenylpropionate ester (n = 7) than with the decanoate ester (n = 6), each given as 100 mg in 4 ml of arachis oil into the gluteal muscle.8
Time to peak~24 hNo time in hours is given in the published summary of Minto and colleagues, which reports the peak as earlier with the phenylpropionate ester than with the decanoate ester after a single 100 mg injection in healthy men.8
Duration~3 days (72 h)No duration in hours is given in the sources cited. In the same study the phenylpropionate ester produced "the most rapid, but briefest, suppression" of plasma testosterone.8
RouteIMIntramuscular in the studies of Minto, Pourmand, Zawilska and the knee trial summarised by Heintjes; the records of Branda and colleagues, Lev-Ran and Svorcik and Bicikova do not state a route.8,9,10,2

Deeper analysis: nandrolone esters in oil (Minto and colleagues, 1997)

Minto and colleagues, Royal North Shore Hospital, University of Sydney, Journal of Pharmacology and Experimental Therapeutics, 1997, studied healthy men who had blood sampled for plasma nandrolone, testosterone and inhibin before and for 32 days after a single intramuscular injection of 100 mg of nandrolone ester in arachis oil.8 Twenty-three men were randomised into four groups: nandrolone phenylpropionate (n = 7) or nandrolone decanoate (n = 6), each in 4 ml of arachis oil into the gluteal muscle, or nandrolone decanoate in 1 ml into the gluteal (n = 5) or deltoid (n = 5) muscle.8 Plasma nandrolone was influenced by the ester and injection site, with "higher and earlier peaks with the phenylpropionate ester, compared with the decanoate ester", and plasma testosterone was influenced as well, "with the most rapid, but briefest, suppression being due to the phenylpropionate ester".8 The authors conclude that "the side-chain ester and the injection site and volume influence the pharmacokinetics and pharmacodynamics of nandrolone esters in an oil vehicle in men".8 The published summary names no funder, reports no half-life figure, and the full text is not cited here, so numeric peaks and times are not given.8

The chart below is an illustration from a pharmacokinetic model using the app's half-life of 60 hours and time to peak of 24 hours, its one interval shown as studied is the weekly injection of the knee trial, and its dose range stops at 100 mg, the largest single NPP injection in the sources cited.2,8,9

Level over 4 weeks

Interval between doses

Level, as a share of the peak after one 100 mg dose

As studied: weekly (knee trial)2.

An illustration from a pharmacokinetic model using a half-life of 60 hours (2.5 days). It is not a measured level or a suggested dose.

4

Human studies

The clinical reports cited here that include NPP in people date from 1973 to 2008 and cover knee symptoms, recovery after surgery, anaemia from marrow failure, growth in gonadal dysgenesis and the stimulation threshold of the heart.

Table 4.1Human studies6 rows
Study and yearDesignPeopleDose and lengthMain result
Darracott, 1973, as summarised by Heintjes and colleagues, 20042Randomised, double blind, placebo-controlled; method of randomisation not specified; rated low quality.243 military patients with severe unilateral painful patella meeting criteria for chondromalacia patellae; 40 male, 3 female.225 mg intramuscular weekly for 6 weeks (n = 23) against placebo in arachis oil (n = 20), with graded exercises.2Clinical improvement in 20 of 23 on nandrolone and 1 of 20 on placebo (RR 17.39; 95% CI 2.56 to 118.26); bone density increased in 16 of 20 and 1 of 20 (RR 13.91; 95% CI 2.02 to 95.79).2
Pourmand and colleagues, 20089Randomised, placebo-controlled pilot study; blinding is not described in the published summary.954 patients, mean age 70 years, with benign prostatic hyperplasia admitted for open prostatectomy.9100 mg intramuscular before the operation, one pulse dose, against sesame oil.9Symptom score at 24 hours 6.18 +/- 2.81 on NPP against 9.77 +/- 2.15 on placebo (P < 0.001); at 48 hours 4.48 +/- 2.32 against 5.55 +/- 1.84 (P = 0.06); the lower score on NPP is what the authors call "significantly reduced" symptoms on a 6-point scale.9
Zawilska and colleagues, 199010Randomised, three groups.10183 patients over 40 years old having major abdominal surgery.10Group II: nebulized heparin plus one intramuscular injection of 50 mg NPP; Group I: nebulized heparin alone; Group III: subcutaneous heparin.10Deep vein thrombosis in 16% (Group I), 7.9% (Group II) and 7.8% (Group III); clinically important haemorrhagic complications in 1.7%, 1.6% and 7.8%.10
Branda and colleagues, 197711Prospective, randomised, double blind, placebo-controlled.1124 patients entered, 21 evaluable: 7 aplastic anaemia, 6 myelofibrosis, 8 refractory anaemia.11Dose and length not stated in the published summary.116 patients improved, 3 on nandrolone and 3 on placebo; one patient with myelofibrosis improved on placebo alone.11
Lev-Ran, 197712Observation of an untreated group, a group on nandrolone phenpropionate or methandrostenolone and a group on ethinyl estradiol.1240 patients with 45,X gonadal dysgenesis, followed from age 13 to 15 until 18 to 21 years.12Nandrolone phenpropionate or methandrostenolone (15 patients, not reported separately by drug); dose not stated in the published summary.12Ultimate height 143.3 cm treated with either anabolic steroid, 143.2 cm untreated (n = 12) and 144.1 cm on ethinyl estradiol (n = 13); growth velocity was somewhat accelerated by the anabolic steroids during the first year of therapy, and this did not influence the ultimate height.12
Svorcik and Bicikova, 197813Clinical measurements of various drugs.13People not counted in the published summary.13Dose not stated in the published summary.13The summary lists nandrolone phenylpropionate and nandrolone decanoate, in square brackets, among the anabolics that gave "The deepest and most prolonged depression of the stimulation threshold" of the human heart [right ventricle], a lowering of the threshold where other drugs in the same study raised it; high doses of prednisone and 6-methylprednisolone did too, and no doses are stated.13

Deeper analysis: chondromalacia patellae (Darracott, 1973; Heintjes and colleagues, 2004)

Heintjes and colleagues, Erasmus University Rotterdam, Cochrane Database of Systematic Reviews, 2004, summarise Darracott's trial from Current Medical Research and Opinion, 1973, in a review of drugs for patellofemoral pain; the review lists internal support from two Rotterdam departments and no external support.2 They describe a trial of military recruits with unilateral, severe disabling symptoms of chondromalacia patellae, all of whom did graded quadriceps exercises, and rate it a "low quality" study.2 The review concludes: "There is limited evidence from one low quality study that nandrolone phenylpropionate is more effective than placebo for improving clinical symptoms and signs in people with chondromalacia patellae".2 Its own caveat is that "Whether this clinical improvement may be due to the reversal of patellar osteoporosis, or to the muscular hypertrophy it induces, cannot be derived from these results", and it adds that anabolic esters "have significant side effects, such as premature closure of epiphyses, virilisation, liver insufficiency and heart failure".2 The review's summary concludes that nandrolone "may be effective, but is too controversial for treatment of PFPS".2 The review gives allocation concealment as unclear, and notes that the trial did not report pain as a separate outcome and that definitions of its outcome measure "clinical symptoms and signs" have not been reported.2

Deeper analysis: open prostatectomy (Pourmand and colleagues, 2008)

Pourmand and colleagues, Urology Research Centre, Sina Hospital, University of Tehran, Aging Male, 2008, measured early postoperative symptoms (urinary symptoms, incision site pain and general satisfaction) on a 6-point self-administered questionnaire at 24 and 48 hours, and also measured sex hormone binding globulin and testosterone.9 The 24-hour difference favoured NPP, the 48-hour difference did not reach significance, and the authors report that "There was no complication attributed to NP therapy".9 They call it a pilot study and write that "Further studies, longer and repeated pulse injections in a larger number of older men are mandatory to prove the claim".9 The published summary names no funder, no group sizes and no hormone results.9

Deeper analysis: postoperative deep vein thrombosis (Zawilska and colleagues, 1990)

Zawilska and colleagues, Academy of Medicine, Poznan, Folia Haematologica, 1990, gave all three groups heparin in one form or another: Group I a single dose of nebulized heparin (800 IU per kg) the day before surgery, Group II the same plus one 50 mg injection of NPP, and Group III 5000 IU subcutaneous heparin an hour before surgery and every 12 hours for 5 days.10 Deep vein thrombosis was assessed with the 125-I-fibrinogen test, and the authors conclude that a single application of nebulized heparin and the long acting anabolic steroid "is as effective as conventional low-dose subcutaneous heparin administration, but gives less haemorrhagic complications".10 The published summary gives no group sizes, no significance test and no funder; Group I and Group II differ in the single NPP injection (16% against 7.9% deep vein thrombosis), but without those figures the difference cannot be judged.10

Anaemia from marrow failure (Branda and colleagues, 1977)

Branda and colleagues, Archives of Internal Medicine, 1977, conclude that "no substantial improvement of anemia due to marrow failure can be ascribed to nandrolone as given", and report that "No serious drug toxicity was noted".11 The published summary names no funder.11

5

Doses reported in studies

The app's typical dose is 100 to 300 mg a week, and the regimens below are those reported in the cited studies.

Table 5.1Doses reported in studies5 rows
SourceDoseFrequencyLength
Darracott knee trial, summarised by Heintjes and colleagues225 mg intramuscularWeekly6 weeks
Minto and colleagues8100 mg intramuscular, in 4 ml of arachis oilSingle injectionSampled for 32 days
Pourmand and colleagues9100 mg intramuscularOne pulse dose before surgerySingle dose
Zawilska and colleagues1050 mg intramuscularSingle injectionSingle dose
Belkien and colleagues, a different ester and not NPP7100 mg, then 200 mg, of 19-nortestosterone-3-(p-hexoxyphenyl)-propionateWeekly3 weeks, then 10 weeks

The largest amount stated for NPP in the sources cited is 100 mg as one injection, and none of them states a weekly NPP regimen of 100 mg or more, so the app's 100 to 300 mg a week has no counterpart in them for NPP. Belkien and colleagues gave a different ester, not NPP, at 100 mg a week for 3 weeks and then 200 mg a week for 10 weeks to 5 men, and serum nandrolone accumulated.7

In the NPP trials, Pourmand and colleagues report "no complication attributed to NP therapy" after a single 100 mg injection in a pilot study with no group sizes given, and Branda and colleagues report that "No serious drug toxicity was noted", with the dose and length of treatment not stated in the published summary.9,11 Zawilska and colleagues report clinically important haemorrhagic complications in 1.7% of Group I, 1.6% of Group II (heparin plus NPP) and 7.8% of Group III.10 The Cochrane summary of the 25 mg weekly knee trial, the only repeated NPP dosing among the trials cited, gives no adverse event results for it.2

Statements about adverse effects of the class come from reviews and are not measurements of NPP. Heintjes and colleagues write that anabolic esters "have significant side effects, such as premature closure of epiphyses, virilisation, liver insufficiency and heart failure".2 Kicman writes that chronic administration of anabolic steroids, "even those with a very high myotrophic–androgenic index value, such as found with nandrolone (19-nortestosterone), will result in hirsutism and, eventually, virilization of women and children".3 Kicman's table of adverse effects of anabolic steroid administration lists "Suppression of gonadal steroidogenesis", "Testicular atrophy" and that "Recovery of fertility can take from months up to approximately 1 year after cessation of administration, depending on the extent of abuse", and states that "Hepatoxicity is associated with 17α-alkylated steroids (orally active)".3 The same table lists, as class effects, premature closure of the epiphysis in children, gynaecomastia and enlarged nipples in men, an increased risk of thrombotic events with raised LDL, lowered HDL and raised haematocrit, cardiac damage, sudden cardiac death and psychological effects, and Kicman writes that the link to cardiovascular events remains to be clearly established but "the evidence gathered is fairly compelling" and that the effect is "probably underreported".3

In Minto and colleagues' 1997 study, a single 100 mg injection of NPP was followed by plasma testosterone suppression that was "the most rapid, but briefest" of the esters compared.8

7

Bloodwork and markers

The app lists total testosterone, estradiol, prolactin, hematocrit and lipids as markers to follow. Minto and colleagues measured plasma nandrolone, testosterone and inhibin, and Pourmand and colleagues measured sex hormone binding globulin and testosterone.8,9 Kicman's table of adverse effects of anabolic steroids lists raised LDL, lowered HDL and raised haematocrit as class effects3. The summaries of the NPP studies cited do not report estradiol, prolactin, hematocrit or lipid results.

The US Drug Enforcement Administration's 21 CFR 1308.13 lists anabolic steroids in Schedule III, "including its salts, esters and ethers", and its list includes "(64) nandrolone (17β-hydroxyestr-4-en-3-one)".14

WADA's 2026 Prohibited List names nandrolone (19-nortestosterone) in S1.1, anabolic androgenic steroids "When administered exogenously", and the entry ends "and other substances with a similar chemical structure or similar biological effect(s) including their esters".15 Class S1 is "PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION)" and "All prohibited substances in this class are non-Specified Substances".15 A search of the list's text for phenylpropionate and phenpropionate returned no match for nandrolone phenylpropionate as a separate entry.15

Two analytical studies built assays that include NPP: Tretzel and colleagues, German Sport University Cologne, 2014, a dried blood spot screening assay for eight anabolic steroid esters including nandrolone phenylpropionate, and Fabresse and colleagues, 2017, a method for eight esters in hair that includes nandrolone phenylpropionate and was applied to two real cases.16,17 Both are method papers, and neither summary reports a detection window for NPP after a dose.16,17

The sources cited give no numeric half-life, bioavailability, time to peak or weekly regimen for NPP in people, so the app's 60 hours, 95%, 24 hours and 100 to 300 mg a week are not backed by them.8 Only the published summary of Minto and colleagues' pharmacokinetic study is cited, and its full text may report numeric peaks and times.8 The human trials of NPP cited here date from 1973 to 2008, the largest has 183 patients, and the sources describe them as a low quality study, a pilot study and a trial with 21 evaluable patients.2,9,10,11 The sources cited report no study of NPP in healthy men beyond the single-dose pharmacokinetic study, and no prolactin, estradiol, hematocrit or lipid results for NPP. The Cochrane review words the evidence for NPP in knee symptoms as "limited evidence from one low quality study", and none of the sources cited rates the evidence for NPP as moderate, which is the app's grade.2

What is nandrolone phenylpropionate (NPP)?

Nandrolone phenylpropionate (NPP) is the phenylpropionate ester of nandrolone (19-nortestosterone), and nandrolone phenpropionate and Durabolin are among its listed names.1 Kicman states that esters of nandrolone are hydrolysed by blood esterases to the active compound.3

What is the half-life of NPP?

The app's half-life for NPP is about 60 hours (~2.5 days), and none of the sources cited reports a half-life for NPP in people. Minto and colleagues, 1997, reported higher and earlier peaks of plasma nandrolone with NPP (n = 7) than with nandrolone decanoate (n = 6) after single 100 mg injections in 4 ml of arachis oil into the gluteal muscle in healthy men.8

How does NPP differ from nandrolone decanoate?

In Minto and colleagues' study of 23 healthy men given 100 mg, the comparison of the two esters was NPP (n = 7) against decanoate (n = 6), both in 4 ml of arachis oil into the gluteal muscle, and plasma nandrolone peaks were higher and earlier with the phenylpropionate ester.8 Plasma testosterone suppression was the most rapid but briefest with the phenylpropionate ester.8 The summary states that after decanoate injection the highest bioavailability and peak nandrolone levels were seen with the 1 ml gluteal injection, and it reports no comparison of that group with NPP.8

Is NPP banned by WADA?

WADA's 2026 Prohibited List names nandrolone in S1.1, with "including their esters", and class S1 is prohibited at all times, in and out of competition.15 A search of the list's text found no separate entry for nandrolone phenylpropionate.15

Is NPP a controlled substance in the US?

21 CFR 1308.13 lists nandrolone among the Schedule III anabolic steroids, "including its salts, esters and ethers".14

Has NPP been studied in people?

Randomised trials of NPP in people include a 43-patient knee trial of 25 mg weekly for 6 weeks, a 54-patient trial of a single 100 mg dose before prostate surgery, a 183-patient trial of a single 50 mg dose with heparin and a 21-patient anaemia trial.2,9,10,11 The sources describe the knee trial as low quality and the prostate trial as a pilot study, and the anaemia trial found no substantial improvement ascribed to nandrolone.2,9,11

What side effects are reported with NPP?

Pourmand and colleagues reported "no complication attributed to NP therapy" after a single 100 mg injection in a pilot study, and Branda and colleagues reported that "No serious drug toxicity was noted".9,11 Reviews list virilisation and suppression of gonadal steroidogenesis for anabolic steroids as a class; Heintjes and colleagues list liver insufficiency for anabolic esters, Kicman ties hepatotoxicity to 17α-alkylated steroids (orally active), and Kicman lists cardiovascular effects as class effects too.2,3

What is Durabolin?

Durabolin is a name listed for nandrolone phenylpropionate in PubChem.1 The 1973 knee trial summarised in a Cochrane review used "nandrolone phenylpropionate (Durabolin)" 25 mg.2

Which analytical methods detect NPP?

Tretzel and colleagues, 2014, built a dried blood spot screening assay that includes nandrolone phenylpropionate, and Fabresse and colleagues, 2017, built a hair method that includes it.16,17

12

References

  1. National Center for Biotechnology Information. Nandrolone Phenylpropionate, PubChem compound record (CID 229455), 2026. PubChem CID 229455
  2. Heintjes E, et al. Pharmacotherapy for patellofemoral pain syndrome. Cochrane Database Syst Rev 2004. PMC8276350
  3. Kicman AT. Pharmacology of anabolic steroids. Br J Pharmacol 2008. PMC2439524
  4. National Library of Medicine. PubMed search for nandrolone phenylpropionate, nandrolone phenpropionate or phenylpropionate nandrolone in the title or abstract, run 16 November 2026. PubMed search
  5. National Library of Medicine. DailyMed label search by drug name (nandrolone phenpropionate, nandrolone phenylpropionate, Durabolin, nandrolone), run 16 November 2026. DailyMed search
  6. Health Canada. Drug Product Database, active ingredient search for nandrolone, searched 16 November 2026. Health Canada DPD
  7. Belkien L, et al. Pharmacokinetics of 19-nortestosterone esters in normal men. J Steroid Biochem 1985. PMID 4010287
  8. Minto CF, et al. Pharmacokinetics and pharmacodynamics of nandrolone esters in oil vehicle: effects of ester, injection site and injection volume. J Pharmacol Exp Ther 1997. PMID 9103484
  9. Pourmand G, et al. Anabolic-androgenic steroid effects on early morbid symptoms after open prostatectomy: a pilot study. Aging Male 2008. PMID 18821287
  10. Zawilska K, et al. Nebulized heparin and anabolic steroid in the prevention of postoperative deep vein thrombosis following elective abdominal surgery. Folia Haematol Int Mag Klin Morphol Blutforsch 1990. PMID 1709903
  11. Branda RF, Amsden TW, Jacob HS. Randomized study of nandrolone therapy for anemias due to bone marrow failure. Arch Intern Med 1977. PMID 318825
  12. Lev-Ran A. Androgens, estrogens, and the ultimate height in XO gonadal dysgenesis. Am J Dis Child 1977. PMID 868816
  13. Svorcik C, Bicikova L. Effect of drugs on the stimulation threshold of the human heart. Cor Vasa 1978. PMID 28897
  14. US Drug Enforcement Administration. 21 CFR 1308.13 Schedule III. Electronic Code of Federal Regulations, 2026. 21 CFR 1308.13
  15. World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. WADA 2026 list
  16. Tretzel L, et al. Use of dried blood spots in doping control analysis of anabolic steroid esters. J Pharm Biomed Anal 2014. PMID 24713476
  17. Fabresse N, et al. Detection and quantification of 12 anabolic steroids and analogs in human whole blood and 20 in hair using LC-HRMS/MS: application to real cases. Int J Legal Med 2017. PMID 28236045